PDCD1 and familial pancreatic carcinoma: Clinical trials exploring the combination of chemotherapy agents with immune checkpoint inhibitors CTLA-4 and PD-1 have shown interesting data in unresectable, locally advanced and metastatic cases of pancreatic cancer but remain low for resectable cases (Nomi et al. 2007; Kamath et al. 2019; Thind et al. 2017).